This meta-analysis involving 872 individuals showed that SGLT2 inhibitors may reduce body weight in adults with overweight or obesity but not diabetes, and the result is similar to that of a previous meta-analysis, which showed a reduction in body weight (MD: 1.74 kg, 95% CL: -2.03 to -1.45) compared with placebo in diabetes. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.